Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Updated on 26 January 2021


Cancer immunotherapy with immunostimulatory antibodies targeting the CTLA-4 or PD-1/PD-L1 pathways has demonstrated its efficacy in variable proportions of cancer. For metastatic colorectal cancer (mCRC) it appeared that only the small subgroup of patients with MSI-H tumors (microsatellite instability-high phenotype) had a clinically meaningful response to the anti-PD-1- L1 antibodies. In the majority group of non-MSI-H CRC (90-95% of patients), current research expect that additional means would be able to render the tumor "immunogenic" (like MSI-H CRC) and increase the intratumoral immune infiltrate which is the prerequisite to observe a benefit from PD1-PD-L1 inhibitors. Combinations of immune checkpoint inhibitors and procedures that increase intratumoral immune responses, such as targeted therapy, are actively explored.

Condition Colorectal Neoplasms Malignant
Treatment Irinotecan, Avelumab, Cetuximab Injection
Clinical Study IdentifierNCT03608046
SponsorCliniques universitaires Saint-Luc- Université Catholique de Louvain
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Age 18 and over, Performance status: ECOG 0-1
Histologically proven metastatic colorectal adenocarcinoma, refractory to standard chemotherapy (fluoropyrimidine, oxaliplatin, irinotecan) and anti-EGFR treatment (only for RAS WT tumor)
Measurable disease (RECIST 1.1)
Metastasis accessible for sequential biopsies
Patient consent for metastasis biopsies in the study protocol
BRAF V600E wild-type and MSS tumors
Adequate normal organ and marrow function (see adequate section of the full protocol for definition)
Life expectancy of at least 4 months

Exclusion Criteria

Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy that are not indicated in the study protocol
Systemic autoimmune disease
Chronic treatment with corticoids or other immunosuppressive treatment
Clinically significant cardiac, lung or general disease despite optimal treatment
Non-progressive disease following irinotecan-based treatment
For RAS WT, non-progressive disease following anti-EGFR treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note